Pfizer Inc. (NYSE:PFE) Shares Sold by SevenBridge Financial Group LLC

SevenBridge Financial Group LLC trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 22.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 131,644 shares of the biopharmaceutical company's stock after selling 37,323 shares during the quarter. SevenBridge Financial Group LLC's holdings in Pfizer were worth $3,361,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. OneAscent Financial Services LLC lifted its position in Pfizer by 44.8% during the fourth quarter. OneAscent Financial Services LLC now owns 36,999 shares of the biopharmaceutical company's stock valued at $982,000 after purchasing an additional 11,447 shares during the period. Cinctive Capital Management LP lifted its holdings in shares of Pfizer by 7.1% in the 4th quarter. Cinctive Capital Management LP now owns 181,302 shares of the biopharmaceutical company's stock valued at $4,810,000 after buying an additional 12,060 shares during the period. Perritt Capital Management Inc boosted its stake in shares of Pfizer by 2.7% in the fourth quarter. Perritt Capital Management Inc now owns 19,938 shares of the biopharmaceutical company's stock worth $529,000 after buying an additional 522 shares during the last quarter. WESCAP Management Group Inc. grew its holdings in Pfizer by 29.2% during the fourth quarter. WESCAP Management Group Inc. now owns 13,275 shares of the biopharmaceutical company's stock worth $352,000 after acquiring an additional 3,000 shares during the period. Finally, Private Portfolio Partners LLC grew its holdings in Pfizer by 57.8% during the fourth quarter. Private Portfolio Partners LLC now owns 48,873 shares of the biopharmaceutical company's stock worth $1,297,000 after acquiring an additional 17,907 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PFE. Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.41 during midday trading on Thursday, hitting $24.30. The company had a trading volume of 53,412,700 shares, compared to its average volume of 39,300,511. Pfizer Inc. has a twelve month low of $24.26 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business's 50-day simple moving average is $25.98 and its 200-day simple moving average is $26.83. The stock has a market cap of $137.79 billion, a price-to-earnings ratio of 17.23, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.